AbbVie’s Humira (adalimumab) is standing up to US biosimilar competition better than expected. That was the message from the firm’s management team as the originator reported second-quarter results, including Humira sales that fell by 26% in the US to $3.45bn as global sales dropped by a quarter to $4.012bn.
AbbVie Hails Humira’s Resistance To US Competition
Adalimumab Originator Does Better Than Expected Against Biosimilar Pressure In Q2
As the firm reported Q2 results, AbbVie management offered some insights into how Humira is standing up against US biosimilar adalimumab competition a little better than expected.
More from Biosimilars
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
More from Products
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.